ALPHARETTA, Ga., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ: CLSD ), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced it has received a Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Number 15/086,485 entitled, “Methods and Devices for the Treatment of Ocular Diseases in Human Subjects.”
Once the administrative process is complete, the U.S. Patent that issues from this application will provide intellectual property protection for methods of treating posterior ocular disorders by non-surgically administering axitinib to the suprachoroidal space of the eye. This patent represents one in a series of filings protecting the use of the suprachoroidal space as a location in the eye to dose drug that provides for higher bioavailability to target retinal and choroidal diseases, regardless of the method of administration.
In 2016, Clearside selected axitinib as the lead compound for its development program for the treatment of neovascular age-related macular degeneration (“wet AMD”) through suprachoroidal administration. In preclinical models, we observed that axitinib had a long drug half-life and high bioavailability in the tissues of the back of the eye. Axitinib targets all vascular endothelial growth factor receptors, in addition to other key receptors involved in angiogenesis.
“This is the seventh patent allowance in the United States related to our proprietary approach for the treatment of blinding diseases,” commented Clearside’s Chief Executive Officer and President, Daniel H. White. “Our IP estate provides important protection for opportunities to provide treatment for eye diseases via suprachoroidal drug administration.”
About Clearside
Clearside Biomedical, Inc., headquartered in Alpharetta, GA, is a publicly traded, ophthalmic biopharmaceutical company that envisions a world without blindness. Clearside relentlessly pursues transformative, elegant, precise solutions to restore and preserve vision. Clearside is developing advanced clinical and pre-clinical candidates using a proprietary treatment approach offering unprecedented access to the back of the eye through the suprachoroidal space (SCS™). This offers potentially meaningful treatment benefit to patients suffering from sight threatening diseases like uveitis, retinal vein occlusion, diabetic macular edema and wet AMD. To learn more about how Clearside is changing ophthalmology, please visit us at www.clearsidebio.com .
Contacts Company: Charles Deignan Chief Financial Officer 678-270-4005 charlie.deignan@clearsidebio.com Investors: Matthew Beck The Trout Group 646-378-2933 mbeck@troutgroup.com
